Blockchain startup Mediledger has published the results of its FDA blockchain pilot for the pharmaceutical supply chain. Numerous separate groups applied to the FDA and ran pilots for the Drug Supply Chain Security Act (DSCSA) 2023 milestone for package-level tracing, with this being one of the largest groups. Mediledger’s participants included all three major U.S. wholesalers, seven out of ten of the world’s largest pharmaceutical companies, massive dispensers Walgreens and Walmart, as well as logistics firms such as FedEx.
But the group also incorporated smaller wholesalers, manufacturers, pharmacies and logistics companies, and standards body GS1 US.
The ultimate aim is to be able to trace pharmaceuticals from the point of dispensing back to the manufacturer. Given that wholesalers sit between manufacturers and dispensers for the vast majority of drug sales, they play a crucial role. The big three U.S. wholesalers, AmerisourceBergen, McKesson and Cardinal Health account for 94% of sales and all participated in the Mediledger trial.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
